CN Patent

CN113214231B — 5ht2a受体拮抗剂及其医疗应用

Assigned to Huihan Medical Technology Co ltd · Expires 2022-04-08 · 4y expired

What this patent protects

本发明提供了一种具有中枢神经系统疾病治疗作用的式I结构的化合物，其具有5‑HT2A受体拮抗剂或反向激动剂活性，并且对5‑HT2A受体的选择性高、心脏毒性低、代谢稳定性好，可以用于治疗某些精神疾病(如抑郁症、焦虑症、精神病、精神分裂症、失眠、自闭症)及与中枢神经系统退行性疾病(如阿尔兹海默症、帕金森病、亨廷顿病、路易小体痴呆症)相关或者并发的精神紊乱症状。

USPTO Abstract

本发明提供了一种具有中枢神经系统疾病治疗作用的式I结构的化合物，其具有5‑HT2A受体拮抗剂或反向激动剂活性，并且对5‑HT2A受体的选择性高、心脏毒性低、代谢稳定性好，可以用于治疗某些精神疾病(如抑郁症、焦虑症、精神病、精神分裂症、失眠、自闭症)及与中枢神经系统退行性疾病(如阿尔兹海默症、帕金森病、亨廷顿病、路易小体痴呆症)相关或者并发的精神紊乱症状。

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: CN113214231B
Jurisdiction: CN
Classification: —
Expires: 2022-04-08
Drug substance claim: No
Drug product claim: No
Assignee: Huihan Medical Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.